Loading…
Lobbying Spend
—
Filings
174
Firms Hired
4
Active Period
1999–2017
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 9
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Track development of the Food and Drug Administration Reauthorization Act (H.R. 2430/S. 934) and issues of interest to the pharmaceutical industry.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2430
FDA Reauthorization Act of 2017
2017 · second_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Track development of the Food and Drug Administration Reauthorization Act (H.R. 2430/S. 934) and issues of interest to the pharmaceutical industry.
Client expense: — · Firm income: $30,000
Matched citations: S. 934
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 9
21st Century Cures Act
2017 · first_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act). Issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 9
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Client expense: — · Firm income: $30,000
Matched citations: S. 1137
American Health Care Act of 2017
2017 · first_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education about the necessity and safety of vaccines; American Health Care Act (HR 1628); general issues related to the 340B drug pricing program;
Client expense: — · Firm income: $30,000
Matched citations: HR 1628
Strengthening Public Health Emergency Response Act of 2016
2016 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Act (PL 114-255); and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (Further Continuing and Security Assistance Appropriations Act, PL 114-254). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases and insulin pricing.
Client expense: — · Firm income: $40,000
Matched citations: HR 3299
Zika Response Appropriations Act, 2016
2016 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Act (PL 114-255); and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (Further Continuing and Security Assistance Appropriations Act, PL 114-254). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases and insulin pricing.
Client expense: — · Firm income: $40,000
Matched citations: HR 5243
Medicare Prescription Drug Price Negotiation Act of 2015
2016 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in or changes to reimbursement for medicines under the Medicare Part B program; and Senate Finance Chronic Care Work Group (no specific legislation).
Client expense: — · Firm income: $40,000
Matched citations: S. 31
Public Health Emergency Response and Accountability Act
2016 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Act (PL 114-255); and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (Further Continuing and Security Assistance Appropriations Act, PL 114-254). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases and insulin pricing.
Client expense: — · Firm income: $40,000
Matched citations: S.3280
21st Century Cures Act
2016 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act). Issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis. Issues related to insulin and vaccines, no specific legislation.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 9
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Client expense: — · Firm income: $45,000
Matched citations: S. 1137
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016
2016 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (H.R. 3049/S. 1800). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B), Tropical Disease PRV Program (S.2512/H.R.4400); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 3049
Strengthening Public Health Emergency Response Act of 2016
2016 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (H.R. 3049/S. 1800). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B), Tropical Disease PRV Program (S.2512/H.R.4400); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases.
Client expense: — · Firm income: $40,000
Matched citations: HR 3299
Adding Zika Virus to the FDA Priority Review Voucher Program Act
2016 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (H.R. 3049/S. 1800). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B), Tropical Disease PRV Program (S.2512/H.R.4400); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases.
Client expense: — · Firm income: $40,000
Matched citations: H.R.4400
Zika Response Appropriations Act, 2016
2016 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (H.R. 3049/S. 1800). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B), Tropical Disease PRV Program (S.2512/H.R.4400); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases.
Client expense: — · Firm income: $40,000
Matched citations: HR 5243
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016
2016 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (H.R. 3049/S. 1800). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B), Tropical Disease PRV Program (S.2512/H.R.4400); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases.
Client expense: — · Firm income: $40,000
Matched citations: S. 1800
Adding Zika Virus to the FDA Priority Review Voucher Program Act
2016 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (H.R. 3049/S. 1800). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B), Tropical Disease PRV Program (S.2512/H.R.4400); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases.
Client expense: — · Firm income: $40,000
Matched citations: S.2512
Medicare Prescription Drug Price Negotiation Act of 2015
2016 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Issues related to the Medicare Part D prescription drug benefit and possible changes thereto, including the "Medicare Prescription Drug Price Negotiation Act" (S. 31); possible reductions in or changes to reimbursement for medicines under the Medicare Part B program; and Senate Finance Chronic Care Work Group (no specific legislation).
Client expense: — · Firm income: $40,000
Matched citations: S. 31
Public Health Emergency Response and Accountability Act
2016 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Education and awareness of the need for immunizations, pandemic/biodefense funding; the 21st Century Cures Initiative; and education/awareness of diabetes and its treatment. Adequacy of funding for the FDA (H.R. 3049/S. 1800). Possible changes to the 340B drug pricing program. General issues related to access to adult vaccines. Issues related to Zika outbreaks (HR 5243/S 3900/HR 32525 Division B), Tropical Disease PRV Program (S.2512/H.R.4400); Pediatric Review Voucher Extension (PL 114-229)and Public Health Emergency Response Act (HR 3299/S.3280). General issues related to value of prescription medicine for chronic diseases.
Client expense: — · Firm income: $40,000
Matched citations: S.3280
21st Century Cures Act
2016 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the 21st Century Cures Initiative, including all provisions of H.R. 6, To accelerate the discovery, development, and delivery of 21st century cures and for other purposes (21st Century Cures Act). Issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 6
Monitored consideration of patent legislation; international intellectual property issues; general issues related to patent settlements; and all provisions of H.R. 9, the Innovation Act; and S. 1137, Protecting American Talent and Entrepeneurship Act of 2015.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 9
Source: Senate LDA